Autoinhibition can identify rare driver mutations and advise pharmacology.

Abstract excerpt

Identification of protein mutations that drive cancer is a major challenge. A primary reason is that driver mutations are principally identified by their high frequency even though they can also be rare. Driver mutations can locate at functional (binding or active) sites. We dub these orthosteric drivers. However, often they are allosteric drivers. Identification is particularly formidable for rare allosteric...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Allosteric Regulation
• Share to Antineoplastic Agents